2nd annual Pharma and Biotech IP Summit


Fiona Bor.JPG
Fiona Bor
Head, intellectual property, Mereo Biopharma
Fiona Bor is head of intellectual property for Mereo Biopharma and is based in London, having previously been vice president and global head of regional intellectual property at Mylan. Ms Bor graduated in natural sciences from the University of Cambridge before completing a PhD at the Medical Research Council in the United Kingdom, and a post-doctorate at Harvard Medical School. She began her career as a patent attorney at SmithKline Beecham (later GlaxoSmithKline), qualifying and working as a UK and European patent attorney. She spent two years in private practice before joining Teva and later Mylan. Ms Bor is also qualified as a UK patent attorney litigator and has substantial experience of UK High Court litigation and litigation in other jurisdictions. She sits on the governance board of the Patent Examination Board, is a member of the BioIndustry Association’s IP Advisory Committee and regularly speaks at conferences.
+ Show Details
Okan Can.JPG
Okan Can
Partner, Deris

Okan Can, a partner at DERIS, counsels and represents market-leading companies in IP litigation, IP strategy and technology licensing. He qualified as a lawyer at Istanbul University and has developed a reputation as a leading IP expert through his work as a trademark and patent attorney. Mr Can is known for finding solutions to complex cases and achieving the highest compensation in Turkey for IP licensing disputes. He advises international clients on IP litigation, IP strategy and technology licensing.

As a regular guest speaker at IP seminars, universities and conferences, Mr Can’s experience in IP litigation and alternative dispute resolution is highly regarded. He has contributed articles to various publications, including the International Law Office, IAM, Managing Intellectual Property, Mondaq and Getting the Deal Through.

Mr Can has been recognised by a range of leading international publications, including Best Lawyers in Turkey and World Trademark Review.

+ Show Details
Ben Clossick Thomson.jpg
Ben Clossick Thomson
Global litigation counsel, Mylan
Ben Clossick Thomson is a barrister with an academic background in theoretical physics and bioethics. He trained with specialist IP chambers 8 New Square and One Essex Court before joining Milbank Tweed as the founding associate of its IP litigation team. During his time there and subsequently at Arnold & Porter, Mr Clossick Thomson focused his practice on multi-jurisdictional patent litigation in technologies as diverse as mobile telephony to pet food manufacturing. Now global litigation counsel at healthcare company Mylan, Mr Clossick Thomson manages patent litigation, as both patentee and defendant, spanning Australia, Japan, India and Europe.
+ Show Details
Andy Cook.jpg
Andrew Cook
Senior patent attorney, AstraZeneca
Andrew Cook is a senior patent attorney at AstraZeneca in Cambridge, United Kingdom, where he heads the IP team responsible for all of AstraZeneca’s supplementary protection certificate and patent term extension filings globally. He is also the IP attorney responsible for a number of AstraZeneca’s on-market oncology and respiratory products, as well as various pipeline assets. Mr Cook is an experienced UK solicitor and a UK and European Patent Office patent attorney. He studied law at Oxford University, working as a solicitor in a large UK law firm, before following his passion for science and completing a PhD in chemistry at the University of Leeds. He then worked at AstraZeneca for a number of years as a research scientist, medicinal chemistry team leader and drug discovery project leader before entering the IP world.
+ Show Details
David Cottam.jpg
David Cottam
Senior director and associate general patent counsel, respiratory, Teva Pharmaceuticals
David Cottam obtained a bachelor’s degree in microbiology before completing a doctorate in cell biology at the University of Sheffield. He worked on gene therapy and stem cell modulation while a Fogarty Fellow at the National Institute of Health, United States, before returning to the United Kingdom to read a law degree and qualify as a barrister. He is a chartered UK and European patent attorney and a representative before the EU Intellectual Property Office for registered designs and trademarks. He has worked in private practice and in industry and has been recognised as a Corporate IP Star by Managing Intellectual Property. Mr Cottam is responsible for global IP support for Teva Pharmaceuticals’ respiratory therapeutic area. His expertise includes medical device and formulation IP capture and prosecution, global IP clearance for device and drug combination products, extensive European Patent Office opposition and appeal work and global litigation support.
+ Show Details
Michael Dougherty.jpg
Michael P Dougherty
Partner, Hogan Lovells
Michael P Dougherty litigates patent cases in bench and jury trials before the US district courts and the US International Trade Commission (ITC). He has represented brand pharmaceutical companies in suits against generic drug makers under the Hatch-Waxman Act and has played major roles in landmark ITC cases involving recombinant erythropoietin. He has represented major brand companies such as Hoffmann-La Roche, Merck and Schering in district court actions against various generic abbreviated new drug application filers.
+ Show Details
Paul Fehlner.jpg
Paul Fehlner
Principal consultant, Life Sciences Innovation, LLC
Paul Fehlner is the principal of Life Sciences Innovation LLC, where he advises on complex IP business strategy, providing business development and licensing support and coaching legal and IP professionals. Previously, he was head of intellectual property at Novartis Pharma, where his team obtained, maintained and enforced IP rights. Dr Fehlner joined Novartis in 2008 from Baker Botts, where he specialised in IP counselling and litigation in the pharmaceutical, biotechnology and medical device industries. He has also been an associate and partner at Darby & Darby, biotechnology counsel for Rhône-Poulenc Rorer and an associate at boutique IP firm Klauber & Jackson. Dr Fehlner began his career in 1990 as a law clerk at Pennie & Edmonds.

Dr Fehlner has a BSc in chemistry from Haverford College (high honours), a PhD in immunology and biochemistry from Rockefeller University and a JD from Fordham University School of Law.
+ Show Details
Patricia Hec.jpg
Patricia Hec
Head, legal oncology, France, Novartis Pharma
Patricia Hec is head of legal oncology for France at Novartis Pharma. She also manages IP issues for Novartis oncology products in France. This includes using IP defence and litigation to ensure that IP rights and regulatory exclusivities are respected. Ms Hec works closely with Novartis’s global IP teams and external counsel on France-specific regulations and IP case law.
Ms Hec joined Novartis in 2013 from a technology transfer office, where she was head of legal and intellectual property. Previously, she worked for various scientific research institutions, where she specialised in IP and technology transfer, mainly in the life sciences field. She has also practised IP and technology transfer in the material, engineering and IT sciences fields.
Ms Hec has a Master II degree in business law from the Grenoble Graduate School of Business and the University of Grenoble, where she specialised in intellectual property.
+ Show Details
Michelle Jones.jpg
Michelle Jones
Head, intellectual property, Astex Pharmaceuticals
Michelle Jones is a European and chartered UK patent attorney. She joined Astex Therapeutics (now Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceuticals) – a leader in fragment-based drug discovery – in 2000.

Handling a global portfolio of pre-clinical, clinical and marketed pharmaceutical compounds, Dr Jones is experienced in a wide range of areas, including European, US and foreign patent practice, as well as freedom-to-operate and IP licensing strategies. She has extensive experience of IP due diligence activities to support collaboration and licensing initiatives, external fundraising and investment decisions and research collaboration agreement negotiations. She has also managed trademark protection issues for brand names, house marks and domain names.

Dr Jones has a BSc (hons) from the University of Birmingham and a PhD from the University of Cambridge. She is a member of the UK BioIndustry Association IP Advisory Committee and a fellow of the Royal Society of Chemistry.
+ Show Details
Siddharth Kusumaker.jpg
Siddharth Kusumakar
Senior associate, Powell Gilbert LLP

Siddharth Kusumakar, a senior associate at London-based specialist IP firm Powell Gilbert LLP, advises on all aspects of contentious IP law, with a particular focus on multi-jurisdictional patent litigation for clients in the life science and technology sectors.

Mr Kusumakar is an IP litigator with a strong technical background. He advises clients across a broad range of technologies, particularly in disputes that have an international element and involve complex technical issues. He has particular experience of patent litigation in the pharmaceutical, biotechnology and medical device fields, often coordinating simultaneous litigation across Europe and North America.

Mr Kusumakar has represented clients in a number of patent trials, including some of the most high-profile cases to come before the UK Patents Court in recent years.

+ Show Details
Ewan Nettleton.jpg
Ewan Nettleton
Senior patent counsel, oncology, Novartis Pharma AG
Ewan Nettleton is senior patent counsel at Novartis Pharma AG in Switzerland, where he works on global pharmaceutical litigation coordination projects. This involves managing IP and related litigation in a wide range of jurisdictions. Before joining Novartis in September 2010, Mr Nettleton was an associate at Bristows, specialising in IP law with an emphasis on litigation. He has been a qualified UK solicitor since 2002 and has an MA in chemistry and a DPhil in protein chemistry from Balliol College, Oxford, as well as a diploma in IP law and practice from Bristol University. Mr Nettleton is a member of the Royal Society of Chemistry.
+ Show Details
Birgit Verbeure.png
Birgit Verbeure
Director, intellectual property, Galapagos NV
In 2017 Birgit Verbeure joined the patent team of Galapagos NV – a clinical-stage biotech company specialised in the discovery and development of small molecule medicines with novel modes of action. After initially training as a patent attorney in private practice, Ms Verbeure gained in-house experience and qualified as a European patent attorney at Tibotec, a Johnson & Johnson company specialised in small molecule antivirals which now forms part of Janssen. In 2010 she moved to GlaxoSmithKline, where she supported the company’s vaccines franchise as a biotech patent attorney for seven years. Ms Verbeure is a qualified European and Belgian patent attorney and has a PhD in medicinal chemistry from the University of Leuven.
+ Show Details
Tony Pezzano.jpg
Tony Pezzano
Partner, Hogan Lovells
Tony Pezzano has more than 25 years’ experience in large-scale patent litigation and trials, having acted as lead counsel for major clients in the US district courts (both bench and jury trials) and Section 337 investigations at the US International Trade Commission (ITC). Mr Pezzano has represented Merck/Schering and Hoffmann-La Roche/Roche Palo Alto in numerous Hatch-Waxman patent litigations in the US district courts. He also represented the Hoffmann-La Roche family of companies in the European Patent Office ITC 568 investigation. He has been recognised in the IAM Patent 1000 with regard to his work before the US district courts and the ITC, IP Stars, Managing Intellectual Property, Who’s Who, the US Legal 500, the Super Lawyers Business Edition and New York Super Lawyers. Mr Pezzano is a past president of the ITC Trial Lawyers Association.
+ Show Details
Jennifer Roscetti.jpg
Jennifer Roscetti
Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Jennifer Roscetti practises patent litigation before the US district courts and the US International Trade Commission. She also represents clients before the US Court of Appeals for the Federal Circuit. Her practice encompasses a range of technologies primarily focused on chemical subject matter, such as pharmaceuticals, cosmetics and specialty chemicals.
Ms Roscetti is experienced in representing pharmaceutical patent holders in abbreviated new drug application litigations for blockbuster pharmaceuticals. She has had key responsibilities in all aspects of federal district court litigations – from the initial pleading stage to discovery, motions, claim construction and trial. She provides strategic guidance to clients on infringement, validity and enforceability issues and has served as counsel on litigations involving OxyContin, Opana, Nucynta, Zytiga, Lovaza and Evista.
Ms Roscetti regularly lectures in the United States and abroad on potential challenges and opportunities for the pharmaceutical and biotechnology industries in navigating recent developments in US patent law.
+ Show Details
David Schwartz.jpg
David Schwartz
Partner, Smart & Biggar/Fetherstonhaugh
David Schwartz is a partner in the Ottawa office of Smart & Biggar/Fetherstonhaugh. His practice focuses on patent law, particularly in the fields of biotechnology, pharmaceuticals and chemistry. He advises clients on regulatory matters relating to the Patented Medicines (Notice of Compliance) Regulations, data protection under the Food and Drug Regulations and matters concerning the Patented Medicine Prices Review Board. Mr Schwartz has testified on Canadian patent law reform in the House of Commons and the Senate. He is a former president of the Intellectual Property Institute of Canada. Mr Schwartz has been recognised by a range of leading Canadian and international publications, including The Best Lawyers in Canada, The Canadian Legal LEXPERT Directory, Who’s Who Legal, Managing Intellectual Property’s IP Stars Handbook and LMG Lifesciences. The Best Lawyers in Canada has recognised him as Lawyer of the Year in Biotechnology Law for 2018.
+ Show Details
Jonathan Twaite.jpg
Jonathan Thwaite
Head, patents, Basilea Pharmaceutica Ltd
Jonathan Thwaite began his training as a patent attorney in private practice in the United Kingdom in 2003. He moved to Switzerland to work as a European patent attorney in the crop protection team of Syngenta in 2008, before joining Basilea Pharmaceutica Ltd as head of patents in 2014. Mr Thwaite has a PhD in biochemistry from Cambridge University and an MBA from St Gallen University.
+ Show Details
Tim Whitfield.jpg
Tim Whitfield
Partner, Powell Gilbert LLP
Tim Whitfield, a partner at London-based specialist IP law firm Powell Gilbert LLP, advises clients in contentious IP-related matters across a wide range of technologies, with a particular focus on pharmaceutical sector disputes with an international element.
Mr Whitfield represents clients in the English courts and at the European Patent Office and has a wealth of experience advising clients on the coordination of international patent litigation strategy in the pharmaceutical and medical device fields. In this context, he has experience of infringement and validity proceedings in a wide range of European territories. He also advises on pharmaceutical regulatory issues and supplementary protection certificates.
Mr Whitfield’s strong scientific background allows him to understand the complex technical issues which often arise in the life sciences sector, including with regard to pharmaceutical and biotechnology products, their methods of manufacture and their formulations, medical devices and associated consumables.
+ Show Details
Joff Wild_original.jpg
Joff Wild
Editor, IAM
Joff Wild has been the editor of IAM since it was established in 2003. As a journalist, he has specialised in covering intellectual property since the early 1990s.
Before IAM, Mr Wild was editor of Managing Intellectual Property, Patent World and Copyright World and assistant editor of Trademark World. He has written on IP-related subjects for publications including The Times, the Financial Times, Euromoney, The American Lawyer and Latin Finance, and has appeared on BBC Radio 5 Live and BBC Radio 4 to talk about intellectual property.
He is also editor in chief of the IP division of Globe Business Media Group.
+ Show Details